Announced
Completed
Financials
Tags
Biotechnology
Completed
Private Equity
Cross Border
United States
Single Bidder
Friendly
Acquisition
Minority
biotechnology
Private
Venture Capital
Synopsis
A group of investors including New Enterprise Associates, Deep Track Capital, Sofinnova Investments, and Sands Capital, led a $150m Series A round in Avenzo Therapeutics, a clinical-stage biotechnology company, with participation from INCE Capital, TF Capital, Delos Capital, and Quan Capital. “The team at Avenzo has made great progress over the past 18 months since formation on our mission to advance the next generation of oncology therapies for patients,” Athena Countouriotis, Avenzo Co-Founder, President and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.